Rznomics' RZ 001 is an RNA rewriting gene therapy for recurrent glioblastoma, the aggressive brain cancer that returns in nearly every patient. A 10 patient interim showed manageable side effects, not yet the controlled evidence oncologists need.
Recurrent glioblastoma is the aggressive brain cancer that returns in nearly every patient within months of first-line treatment, and it has resisted decades of drug development. Rznomics, a South Korean biotech, is now reporting interim data from a Phase 1/2a trial of RZ-001, an RNA-editing gene therapy designed to rewrite messenger RNA inside tumor cells and trigger cancer cell death.
The interim, presented at the Asian Society for Neuro-Oncology (ASNO) 2026 meeting in Kanazawa, Japan, on June 13, 2026, drew on 10 enrolled patients out of 20 screened. The reported safety profile was manageable, with no dose-limiting toxicities and no treatment-related Grade 4 or higher adverse events, according to Rznomics' press release. Several patients showed "prolonged disease control" exceeding six months, the company said.
This is the kind of signal that the recurrent glioblastoma field has learned to read with care. Median overall survival after recurrence typically sits under 12 months, and no disease-modifying therapy has held up in a controlled trial. A 10-patient single-arm interim is, by design, the floor of what early-phase data can say. There is no control arm to separate drug effect from natural history, no central efficacy adjudication, and the "several patients" framing is the company's own, not a peer-reviewed endpoint.
The mechanistic premise is what makes RZ-001 worth watching. Rznomics' platform uses trans-splicing ribozymes, RNA enzymes that find a target messenger RNA in tumor cells and replace part of it with a therapeutic gene. The approach is mechanistically distinct from CRISPR base editors, which edit DNA, and from siRNA, which silences RNA. Rznomics says the ribozyme is engineered to express only inside tumor cells, which is the design choice that would, in principle, give it a wider therapeutic window than conventional chemotherapy.
To convert the safety signal into a real therapeutic claim, four hard gates still need to clear. The next trial would have to include a randomized control arm, ideally against the local standard of care at recurrence (typically lomustine or regorafenib), so that response and survival could be attributed to the drug rather than to natural variation in a small, heterogeneous population. It would need a pre-specified proportion of patients with durable control and a clear definition of "control" (stable disease, partial response, or complete response) rather than the vendor-vague "several patients" framing used today. If RZ-001 works, it likely works in a defined molecular subgroup, so a registrational path would probably require a companion diagnostic. And the data would have to clear independent peer review, ideally with publication in a peer-reviewed journal and presentation at a major plenary such as ASCO, SNO, AACR, or ESMO, rather than at a regional meeting like ASNO.
The next look will come when Rznomics reports a fuller Phase 2 cohort, or when the company files for a registration-enabling study. Until then, the constructive read of the June 13 interim is the one Rznomics itself did not put in the headline: the drug cleared a safety bar, and the harder questions are still ahead.